The short interest last reported now is up 3 million shares, and stands at around 40% of float. Meanwhile, the p/e is down to less than 8 at today's price, and earnings keep growing.

Either the short holders have inside information regarding belinostat or leucovorin is coming off the shortage list, or some big plunger is just insane. Since Topotarget keeps rising in Europe, I must discount any inside information on belinostat, and the leucovorin shortage has too many good reasons to continue.

I am betting against insanity, and have increased my long position. Good news on the belinostat trials will finally ignite this, I think, and this should be here before the end of the quarter.